KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Share-based Compensation: 2011-2025

Historic Share-based Compensation for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $7.8 million.

  • Supernus Pharmaceuticals' Share-based Compensation rose 1.97% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 16.80%. This contributed to the annual value of $27.8 million for FY2024, which is 3.72% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Share-based Compensation of $7.8 million as of Q3 2025, which was up 4.24% from $7.5 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Share-based Compensation ranged from a high of $8.1 million in Q1 2025 and a low of $4.0 million during Q1 2022.
  • For the 3-year period, Supernus Pharmaceuticals' Share-based Compensation averaged around $7.1 million, with its median value being $7.5 million (2025).
  • In the last 5 years, Supernus Pharmaceuticals' Share-based Compensation decreased by 21.53% in 2022 and then surged by 58.88% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Share-based Compensation (Quarterly) stood at $4.0 million in 2021, then increased by 5.57% to $4.3 million in 2022, then soared by 51.26% to $6.4 million in 2023, then climbed by 18.42% to $7.6 million in 2024, then grew by 1.97% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $7.5 million for Q2 2025, and $8.1 million during Q1 2025.